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Agreement Between HEDIS Performance 
Assessments in the VA and Medicare 
Advantage: Is Quality in the Eye of the 
Beholder?
Amal N. Trivedi, MD, MPH1,2, Ira B. Wilson, MD, MSc1,  
Mary E. Charlton, PhD3, and Kenneth W. Kizer, MD, MPH4
Abstract
Medicare Advantage (MA) plans and the Veterans Affairs (VA) health care system assess quality of care using standardized 
Healthcare Effectiveness Data and Information Set (HEDIS) performance measures. Little is known, however, about the 
relative accuracy of quality indicators for persons receiving care in more than one health care system. Among Veterans 
dually enrolled in an MA plan, we examined the agreement between MA and VA HEDIS assessments. Our study tested 
the hypothesis that private health plans underreport quality of care relative to a fully integrated delivery system utilizing 
a comprehensive electronic health record. Despite assessing the same individuals using identical measure specifications, 
reported VA performance was significantly better than reported MA performance for all 12 HEDIS measures. The VA’s 
performance advantage ranged from 9.8% (glycosylated hemoglobin [HbA1c] < 7.0% in diabetes) to 54.7% (blood pressure 
< 140/90 mm Hg in diabetes). The overall agreement between VA and MA HEDIS assessments ranged from 38.5% to 62.6%. 
Performance rates derived from VA and MA aggregate data were 1.6% to 14.3% higher than those reported by VA alone. 
This analysis suggests that neither MA plans nor the VA fully capture quality of care information for dually enrolled persons. 
However, the VA’s system-wide electronic health record may allow for more complete capture of quality information across 
multiple providers and settings.
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Introduction
Medicare Advantage (MA) plans and the Veterans Affairs (VA) 
health care system assess quality of care using, among other 
things, standardized Healthcare Effectiveness Data and 
Information Set (HEDIS) performance measures. Performance 
data are publicly reported and influence health plan and pro-
vider payments, so have material consequences. Little is known, 
however, about the relative accuracy of HEDIS data for persons 
receiving care in more than one health care system.
Quality of care performance data in the VA often exceeds 
that reported from private health care settings generally, and 
MA plans specifically.1,2 The differences may partially result 
from dissimilar documentation of care in the data sources 
used for calculating performance rates. Private plans typi-
cally generate performance data using insurance claims or 
abstracted charts, which may fail to capture the entirety of a 
patient’s care compared with VA’s comprehensive electronic 
health record (EHR).3-5 Furthermore, the VA by law cannot 
bill MA plans for services.6 Therefore, MA plans that rely 
on claims to measure quality may have limited ability to 
track care processes that occur in the VA. We examined the 
agreement between MA and VA quality assessments for a 
group of dually enrolled Veterans. Our study tested the 
hypothesis that private health plans underreport quality of 
care relative to fully integrated delivery systems utilizing a 
comprehensive EHR.
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Methods
We identified dually enrolled individuals sampled for the 
same MA HEDIS and VA External Peer Review Program 
(EPRP) HEDIS comparator indicator in either 2008 or 2009. 
We compared performance rates reported by MA plans and 
VA and assessed agreement using McNemar test for mar-
ginal homogeneity. The unit of analysis was the patient. We 
also conducted stratified analyses for individuals having at 
least 10 MA outpatient encounters in the measurement year.
Results
The number of individuals sampled for measurement by both 
systems in the same year ranged from 249 (cholesterol con-
trol in coronary heart disease) to 600 (HbA1c testing in dia-
betes) (Table 1). Reported VA performance was significantly 
better than reported MA performance for all 12 measures, 
with VA’s performance advantage ranging from 9.8% (glyco-
sylated hemoglobin [HbA1c] < 7.0% in diabetes) to 54.7% 
(blood pressure < 140/90 mm Hg in diabetes). The overall 
agreement ranged from 38.5% to 62.6%. Performance rates 
derived from VA and MA aggregate data were 1.6% to 14.3% 
higher than those reported by VA alone.
In sensitivity analyses limited to individuals having at 
least 10 MA outpatient encounters, the VA reported better 
performance than MA for 11 of the 12 measures (ranging 
from 9.9% to 35.9%), and overall agreement between VA 
and MA assessment improved only modestly (ranging from 
48.5% to 78.7%) (Table 2).
Discussion
The VA classified significantly more patients as having met 
outpatient performance targets than did MA plans despite 
assessing the same individuals using identical measure 
specifications. We observed similar degrees of disagreement 
for both processes of care and intermediate outcomes.
MA plans primarily use claims-based methods to assess 
process measures; intermediate outcome assessment typi-
cally requires additional chart review. Pawlson and col-
leagues noted that claims underreport quality relative to 
approaches using both claims and chart review.5 In addition, 
plans typically collect quality information from heteroge-
neous providers in their networks. The VA’s system-wide 
EHR may allow for more complete capture of quality infor-
mation across multiple providers and settings.3,7 In addition, 
the VA often includes clinical reminders for providers to 
document adherence to clinical performance metrics, even 
when care occurs in non-VA settings.8
Among persons enrolled in both systems, performance rates 
that integrate information from both VA and MA sources were 
higher than rates considering information from either system 
alone. Although we did not validate reported performance rates 
Table 1. Agreement Between HEDIS Performance Assessments in the VA and Medicare Advantage.
Condition HEDIS measure Measure type
n assessed 
by both VA 
and MA
Overall rate 
(VA or MA) 
(%)
VA rate 
(%)
MA rate 
(%)
Difference 
(VA − MA, 
%)
Agreement* 
(%)
Diabetes Annual HbA1c Measured Process 600 99.8 98.2 59.3 38.9 57.8
 HbA1c < 7% Intermediate 
outcome
266 59.8 45.5 35.7 9.8 61.7
 HbA1c < 9% (Control) Intermediate 
outcome
265 90.1 87.5 49.1 38.4 56.2
 LDL Cholesterol < 100 
mm Hg
Intermediate 
outcome
258 83.7 78.3 38 40.3 48.8
 BP < 140/90 mm Hg Intermediate 
outcome
377 83.0 79.6 24.9 54.7 38.5
 Retinal Exam Process 587 92.2 85.5 40.4 45.1 41.6
 LDL Cholesterol 
Measured
Process 591 98.3 95.6 53.1 33.5 51.9
 Renal Testing Process 305 98.0 94.1 64.6 29.5 62.6
Coronary heart 
disease
LDL Cholesterol 
Measured
Process 253 99.6 93.7 63.6 30.1 58.1
 LDL Cholesterol < 100 
mg/dL
Intermediate 
outcome
249 83.1 77.1 28.9 48.2 39.8
Cancer screening Women Age 50-69 
Screened for Breast 
Cancer
Process 289 93.1 88.2 39.8 48.4 41.9
 Patients Age 50-
80 Screened for 
Colorectal Cancer
Process 292 91.8 87.7 52.1 35.6 56.2
Note. HEDIS = Healthcare Effectiveness Data and Information Set; VA = Veterans Affairs; MA = Medicare Advantage; HbA1c = glycosylated hemoglobin; LDL = low-density 
lipoprotein; BP = blood pressure.
*McNemar test P < .01 for all values in the column.
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from either system, our findings suggest that neither MA plans 
nor the VA fully capture quality of care information for dually 
enrolled persons. However, the VA may be positioned to report 
substantially better clinical performance because its documen-
tation is more complete. Further studies should compare the 
accuracy of publicly reported quality data from insurers and 
integrated delivery systems, particularly for individuals 
enrolled in multiple health systems.
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Table 2. Agreement Between HEDIS Performance Assessments in the VA and Medicare Advantage Among Patients With ≥ 10 
Medicare Advantage Outpatient Encounters in the Measurement Year.
Condition HEDIS measure Measure type
n assessed by 
both VA and 
MA
Overall rate 
(VA or MA) 
(%)
VA rate 
(%)
MA rate
(%)
Difference 
(VA-MA, 
%)
Agreement*
(%)
Diabetes Annual HbA1c Measured* Process 218 99.5 95.9 78.9 17.0 75.7
 HbA1c < 7%* Intermediate 
Outcome
101 59.4 45.5 35.6 9.9 62.4
 HbA1c < 9% (Control)* Intermediate 
Outcome
100 84.2 78.0 49.0 29.0 59.0
 LDL Cholesterol < 100 
mg/dL*
Intermediate 
Outcome
98 79.6 77.6 45.9 31.7 64.3
 BP < 140/90 mm Hg* Intermediate 
Outcome
133 81.9 78.2 33.1 45.1 47.4
 Retinal Exam* Process 214 90.6 81.8 50.9 30.9 51.4
 LDL Cholesterol 
Measured*
Process 215 98.1 93.0 72.1 20.9 68.8
 Renal Testing* Process 121 100.0 93.4 78.5 14.9 71.9
Coronary heart 
disease
LDL Cholesterol 
Measured*
Process 105 99.1 90.5 72.4 18.1 64.8
 LDL Cholesterol < 100 
mg/dL*
Intermediate 
Outcome
103 79.6 71.8 35.9 35.9 48.5
Cancer screening Women Age 50-69 
Screened for Breast 
Cancer*
Process 96 94.8 88.5 54.2 34.3 53.1
 Patients Age 50-80 
Screened for Colorectal 
Cancer*
Process 109 92.7 87.2 61.5 25.7 63.3
Note. HEDIS = Healthcare Effectiveness Data and Information Set; VA = Veterans Affairs; MA = Medicare Advantage; HbA1c = glycosylated hemoglobin; LDL = low-density 
lipoprotein; BP = blood pressure.
*McNemar test P < .01 for all values in the column.
